Eyecelerator@AAO 2021
Thursday, November 11, 2021
Ernest N. Morial Convention Center
New Orleans
Bring the future of ophthalmology into focus.
CONFERENCE PROGRAM
Breakfast + Registration
7:00 – 8:00 a.m.
8:00 – 8:05 a.m.
Welcome and Overview of Eyecelerator @ AAO 2021
David W. Parke II, MD; Steve Speares; Gil Kliman, MD, Program Director
Welcome!
2021 Advances in Ophthalmic Innovation: Clinical, Commercial, and Capital Markets
8:05 – 8:30 a.m.
2021 Advances in Ophthalmic Innovation: Clinical, Commercial, and Capital Markets
Moderators: Jim Mazzo and Tom Mitro
Speakers:
-
Kristen Harmon Ingenito, MBA, Vice President, Director of Ophthalmics, Market Scope
-
Michael Giaquinto, Senior Managing Director, Medical Supplies & Devices, SVB Leerink
The Magic of Unicorns: How Digital Giants Can Enlighten Ophthalmology
8:30 – 9:15 a.m.
Join moderators Ranya G. Habash, MD and Gil Kliman, MD, when they engage a cohort of leading experts to probe how the digital ophthalmology market is evolving right now. The panel will also forecast the impact of new technology on patient care, clinical data and innovation.
Overview of Digital Health Marketplace
Reed Welch, Managing Director, Raymond James
The session kicks off with an informed overview of the digital health marketplace and a valuable, clear-eyed assessment of what innovators and investors have learned from the recent success of digital “unicorns.”
Moderators: Ranya G. Habash, MD and Gil Kliman, MD
Panel:
-
Hylton Kalvaria, Chief Business Officer, Verana Health
-
Paul McRae, Global Healthcare and Digital Transformation Strategist, Amazon
-
Pam Nesbitt, Global Healthcare Lead, CSE, Microsoft
-
Euan S. Thomson, PhD, President Ophthalmic Devices, Head of Digital Business Unit, Zeiss Medical Technology
-
Reed Welch, Managing Director, Raymond James
Cornea Spotlight
Will Cornea Transplantation Become Obsolete?
9:15 – 10:00 a.m.
Will Cornea Transplantation Become Obsolete?
Moderators: Zaina Al-Mohtaseb, MD and Deepinder K. Dhaliwal, MD, L.Ac.
Panel:
-
Bala Ambati, MD, PhD, MBA, Co-Founder & President, iVeena
-
Nazneen Aziz, PhD, Chief Scientific Officer, Avellino Labs
-
Chuck Hess, Vice President and General Manager, US Surgical, Bausch + Lomb
-
Elizabeth Yeu, MD, Assistant Vice President/Medical Director, Virginia Eye Consultants/Virginia Surgery Center
Treating Keratoconus in 2021
Zaina Al-Mohtaseb, MD
Panel Discussion – What’s New?
Treating Endothelial Dystrophy in 2021
Deepinder K. Dhaliwal, MD, L.Ac.
What will replace Endothelial Keratoplasty?
-
Brian Levy OD, MSc, CMO, EyeYon Medical
-
Greg Kunst, Chief Executive Officer, Aurion Biotech
Panel Discussion
Networking Break
10:00 – 10:30 a.m.
The Intersection of Reimbursement and Innovation
10:30 – 11:15 a.m.
Proposed reimbursement cuts and the evaluation of physician services will have a ripple effect with aftershocks throughout our industry. This session will forecast the impact on investment, innovation, patient care, and physician practice patterns from the perspective of practicing surgeons, industry leaders, and reimbursement experts.
Moderators: Leon W. Herndon, MD and Thomas W. Samuelson, MD
Panel:
-
Jeannette Bankes, Alcon, President and GM Surgical
-
Frank R. Burns, MD, Government Relations Committee Member, ASCRS
-
Erin Powers, MBA, Vice President, Global Marketing & Product Strategy, BVI Medical
-
Nathan M. Radcliffe, MD, Associate Clinical Professor of Ophthalmology, Mount Sinai School of Medicine
-
George A. Williams, MD, Senior Secretary for Advocacy, American Academy of Ophthalmology
Retina Spotlight
Meet the Game-Changing Innovators With the Most Promising Strategies For Impacting Retina
11:15 a.m. – 12:00 p.m.
Moderators Robert L. Avery, MD and Allen C. Ho, MD, will get five innovative companies to open their playbooks and reveal the newest treatments and technologies for retina, while panel experts add insight and analyze the market opportunities.
Moderators: Robert L. Avery, MD and Allen C. Ho, MD
Panel:
-
Wiley Chambers, MD, Supervisory Medical Officer, Ophthalmology, FDA
-
Kevin Clark, Vice President, Ophthalmology Commercial Business Unit, Regeneron
-
Ram Palanki, Senior Vice President of Commercial Strategy & Operations, REGENXBIO, Inc.
-
Reginald J. Sanders, MD, Retina Group of Washington
-
Namrata Saroj, OD, Principal, All Eyes Consulting
Presenting Companies:
-
Annexon Biosciences
Michael Overdorf, MBA, Executive Vice President & Chief Business Officer
-
Apellis Pharmaceuticals
Cedric Francois, MD, PhD, CEO
-
GenSight Biologics
Magali Taiel, MD, Chief Medical Officer
-
Nanoscope Therapeutics
Samarendra Mohanty, PhD, Co-Founder and President
-
Opus Genetics
Benjamin Yerxa, PhD, Acting CEO
Lunch and Networking
12:00 – 1:00 p.m.
Company Showcase Breakout Rooms
1:00 – 2:30 p.m.
A diverse line up of more than 30 companies, from startups to public, will present innovations at all stages in a unique, interactive format. Showcases will include five-minute company presentations followed by a moderated Q+A with panels of seasoned strategics, investors, and KOLs. Audience members will also be invited to ask questions.
Separate breakout rooms will operate simultaneously for each subspecialty. Follow links for company showcase schedules:
Networking Break
2:30 – 3:00 p.m.
New Category Spotlight
Myopia Control: Corrective Lenses, Drugs and Diagnostics
3:00 – 3:45 p.m.
Co-moderators Michael X. Repka, MD and Gil Kliman, MD, engage a panel of new category product innovators striving to mitigate the rapid global rise of myopia through early interventions. Join us for a wide-ranging discussion including a market overview and insights from large and small companies pioneering this new space.
Co-Moderators: Michael X. Repka, MD and Gil Kliman, MD
Overview of Myopia Pandemic
Michael X. Repka, MD, Vice Chair for Clinical Practice, Wilmer Eye Institute
Overview of Companies and Products in the Myopia Control Marketplace
Michael Lachman, President, EyeQ Research
Panel:
-
Thomas W. Chalberg, PhD, MBA, Founder, Exhaura, Ltd.
-
Paul Chamberlain, Director, Research Programs, CooperVision
-
Wiley Chambers, MD, Supervisory Medical Officer, Ophthalmology, FDA
-
Sean Ianchulev, MD, MPH, Founder and CEO, Eyenovia
-
Rajesh K. Rajpal, MD, Chief Medical Officer and Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision
What's Keeping Industry Leaders Up at Night?
3:45 – 4:30 p.m.
This can’t-miss session promises a rare insider's look at the global business of ophthalmology from some of the most forward-thinking executive leaders.
Industry veteran Jim Mazzo will dig deep for insights about each company’s business strategy, examine how the industry is positioned to address key market needs, and even uncover which business challenges remain unsolved for global strategics.
Moderator: Jim Mazzo, Executive Chair, Neurotech Pharmaceuticals
Panel:
-
Ian Bell, President, Global Business and Innovation, Alcon
-
Chris M. Calcaterra, MBA, Chief Operating Officer, Glaukos
-
Jag Dosanjh, SVP, Medical Therapeutics, Allergan, an AbbVie company
-
Warren Foust, Worldwide President, Surgical, Johnson & Johnson
-
Shervin Korangy, President and CEO, BVI Medical
-
Tom Mitro, President and COO, Aerie Pharmaceuticals
-
Anthony J. Wallace, MBA, VP & Franchise Head, U.S. Ophthalmics, Novartis Pharmaceutical Corp.
Closing Bell
4:30 – 5:00 p.m.
Moderator: Gil Kliman, MD
Review of Top Three Companies
Deepinder Dhaliwal MD, L.Ac.
Allen C. Ho MD
Thomas W. Samuelson, MD
Eyes on the Future: What's Coming in 2022
Moderator: Gil Kliman, MD
Panel:
-
Deepinder K. Dhaliwal, MD, L.Ac.
-
Allen C. Ho, MD
-
Thomas W. Samuelson, MD
-
Jim Mazzo
-
Tom Mitro
Closing Remarks - Gil Kliman, MD
Networking Reception
5:00 – 5:45 p.m.